Drugs / ZG2001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06237413 | Aug 2023 → Feb 2026 | cancer | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-04-24 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Regulatory 泽璟制药泛KRAS突变抑制剂ZG2001临床试验申请获得FDA批准 zelgen.com ↗ |
| 2023-04-20 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Regulatory 泽璟制药宣布获批开展甲苯磺酸ZG2001片用于治疗KRAS突变的晚期实体瘤的临床试验 zelgen.com ↗ |
| 2023-02-14 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Regulatory 泽璟制药泛KRAS突变抑制剂ZG2001临床试验申请获NMPA受理 zelgen.com ↗
近日 ，泽璟 制药 收到 国家 药品 监督 管理 局（NMPA）核准 签发 的《受理 通知 书》，公司 自主 研发 的甲 苯磺 酸ZG2001片用 于治 疗KRAS突变 的肿 瘤的 临床 试验 申请 获得 受理 . |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-24 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 泽璟制药泛KRAS突变抑制剂ZG2001临床试验申请获得FDA批准 zelgen.com ↗ |
| 2023-04-20 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 泽璟制药宣布获批开展甲苯磺酸ZG2001片用于治疗KRAS突变的晚期实体瘤的临床试验 zelgen.com ↗ |
| 2023-02-14 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 泽璟制药泛KRAS突变抑制剂ZG2001临床试验申请获NMPA受理 zelgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZG2001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06237413 ↗ |
| Route | Oral | “administered orally” NCT06237413 ↗ |